A phase I trial of the trifunctional anti Her2 × anti CD3 antibody ertumaxomab in patients with advanced solid tumors
Crossref DOI link: https://doi.org/10.1186/s12885-016-2449-0
Published Online: 2016-07-07
Published Print: 2016-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Haense, N.
Atmaca, A.
Pauligk, C.
Steinmetz, K.
Marmé, F.
Haag, G. M.
Rieger, M.
Ottmann, O. G.
Ruf, P.
Lindhofer, H.
Al-Batran, S.-E.
License valid from 2016-07-07